Ariana Pelosci

Patients with hepatocellular carcinoma treated in the frontline setting showed significant improvements in overall survival when treated with donafenib compared with sorafenib.

Judd Moul, MD, discusses the gravity of new data on systemic therapies for men with castration-resistant prostate cancer and how they can be of use during the COVID-19 pandemic.

Patients with muscle invasive urothelial carcinoma who received adjuvant nivolumab experienced a longer disease-free survival compared with those who received placebo.

The phase 2 clinical trial is currently recruiting patients with pediatric low-grade glioma to be treated with DAY101 following a rare pediatric disease designation by the FDA.

Oncologists are trying to remedy the proposed cuts to radiation oncology facilities from the Centers for Medicare and Medicaid Services to lessen health disparities and improve equitable access to care.

Patients with PD-1 inhibitor-resistant melanoma who were treated with ipilimumab plus anti–PD-1 therapy saw significantly better long-term responses than those on ipilimumab alone.

Patients with cancer who are Black or live in low-income areas were found to be at a higher risk of COVID-19 complications, according to recent findings.

Patients with unresectable hepatitis B virus–positive hepatocellular carcinoma have achieved significantly better overall survival and progression-free survival following treatment with sintilimab plus IBI305 vs sorafenib.

Personalized risk assessments that utilize pathogenic variations can help detect CRC early in patients with Lynch Syndrome.

Treatment with trastuzumab, pertuzumab, and docetaxel appears to yield similar efficacy to trastuzumab emtansine in patients with ErbB2-positive breast cancer.

Patients with metastatic triple-negative breast cancer being treated with leronlimab and carboplatin have experienced a decrease in cancer-associated macrophage-like cells and an increase in survival benefit.

Pembrolizumab plus chemotherapy as adjuvant/neoadjuvant therapy demonstrated positive even-free survival outcomes in the KEYNOTE-522 study for patients with triple-negative breast cancer.

Men diagnosed with mCPRC who are treated with 117Lu-PSMA may be assessed using nomograms to help predict outcomes.

Data in patients with colorectal cancer indicates that the Signatera MRD test may help guide treatment decisions in patients with resectable disease.

A new study has adapted CAR to look more human to the body, which will then in turn yield longer remission rates for pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

A new phase 2 study shows that patients who were treated with HIPEC and Carboplatin, did not have better progression-free or overall survival.

Despite some delayed immune responses, the Pfizer COVID-19 vaccine appears safe and effective in patients with cancer who are receiving treatment for their disease.

At the end of 2020, investigators saw more patients being screened for cancer compared with the beginning of the year, although racial and economic disparities still exist for certain tests.

A dose-escalation schedule for neratinib may help some patients with HER2-positive breast cancer better manage severe diarrhea resulting from treatment.

Patients with KRAS-positive NSCLC being treated with rigosertib plus nivolumab demonstrated early efficacy of the combination in a phase 1/2a trial.

FoundationOne CDx, a comprehensive genomic profiling test, has been approved for use in conjunction with brigatinib to test for solid tumors in patients with ALK-positive NSCLC.

Patients with Wilms Tumor-1–positive ovarian cancer have shown promising response to the combination of galinpepimut-s and pembrolizumab.

Based on its potential to prolong overall survival in patients with glioblastoma multiforme, berubicin was granted fast track designation for the FDA for the treatment of recurrent disease.

Final overall survival results from TOURMALINE-MM1 failed to show statistical significance of an ixazomib combination for relapsed/refractory multiple myeloma overall.

Patients who discontinued endocrine therapy early were more likely to have experienced significant mental, physical, and social adverse effects of treatment.

The FDA granted orelabrutinib breakthrough therapy designation for the treatment of relapsed or refractory mantle cell lymphoma.

Patients in the ZUMA-7 trial who were assigned Yescarta (axicabtagene ciloleucel) saw event-free survival by 60% compared to patients who were on a chemotherapy plus stem cell regimen.

Patients with HCC who received atezolizumab/bevacizumab experienced a positive quality of life and improved disease symptoms vs sorafenib.

18FDG-PET was successful in identifying patients with HER2-positive early-stage breast cancer who were more likely to benefit from chemotherapy-free treatment with trastuzumab and pertuzumab.

The Oncologic Drugs Advisory Committee has decided to wait until more results from a clinical trial of retifanlimab are available to make a final decision about approval in squamous cell carcinoma of the anal canal.